1. A novel progress of drug delivery system for organelle targeting in tumour cells
- Author
-
Abdur Rauf Khan, Zhijing He, Aihua Yu, Jianbo Ji, Yanan Zhang, and Guangxi Zhai
- Subjects
Pharmaceutical Science ,Antineoplastic Agents ,02 engineering and technology ,Mitochondrion ,03 medical and health sciences ,symbols.namesake ,Drug Delivery Systems ,0302 clinical medicine ,Organelle ,Tumor Microenvironment ,Animals ,Humans ,Medicine ,Organelles ,business.industry ,Endoplasmic reticulum ,Golgi apparatus ,Neoplastic Cells, Circulating ,021001 nanoscience & nanotechnology ,Cytosol ,Targeted drug delivery ,030220 oncology & carcinogenesis ,Drug delivery ,symbols ,Cancer research ,Nanoparticles ,Stem cell ,0210 nano-technology ,business - Abstract
At present, malignant tumours have become one of the most serious diseases that endanger human health. According to a survey on causes of death in Chinese population in early 1990s, the malignant tumours were the second leading cause of death. In the treatment of tumours, the ideal situation is that drugs should target and accumulate at tumour sites and destroy tumour cells specifically, without affecting normal cells and stem cells with regenerative capacity. This requires drugs to be specifically transported to the target organs, tissues, cells, and even specific organelles, like mitochondria, nuclei, lysosomes, endoplasmic reticulum (ER), and Golgi apparatus (GA). The nano drug delivery system can not only protect drugs from degradation but also facilitate functional modification and targeted drug delivery to the tumour site. This article mainly reviews the targeting of nano drug delivery systems to tumour cytoplasmic matrix, nucleus, mitochondria, ER, and lysosomes. Organelle-specific drug delivery system will be a major mean of targeting drug delivery with lower toxicity, less dosage and higher drug concentration in tumour cells.
- Published
- 2020